Zydus Life Science logo

Zydus Life Science

ZYDUSLIFE NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
1.1L Cr
Volatility
Moderate
P/E Ratio
24.9
EBITDA
₹8,985 Cr
Return on Equity
16.99%
Debt to Equity
0.46
Book Value
₹271.78
EPS
₹41.43
52W High
₹1,205
52W Low
₹835.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Growth Rate

Revenue Growth
17.64% higher than 3Y
Net Income Growth
8.92% lower than 3Y
Cash Flow Change
-68.79% lower than 3Y
ROE
-2.97% lower than 3Y
ROCE
-12.51% lower than 3Y
EBITDA Margin (Avg.)
4.2% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
AI opinion · based on fundamentals
Risk medium

Zydus Lifesciences trades at a market cap of ~₹1,11,330 Cr with a PE of 24.3x and a consistent ROE of ~21% over 3, 5, and 10 years. The company has delivered 16% compounded sales CAGR over 3 years and 32% compounded profit CAGR over the same period, with US formulations now contributing ~47.5% of revenue. However, a recent FDA warning letter at its Baddi facility and slowing TTM profit growth at 5% warrant attention.

Bull Case 8
  • Strong 3-year compounded profit CAGR of 32%, significantly outpacing the 16% sales CAGR over the same period, indicating meaningful margin expansion
  • Consistent ROE of ~21% across 3-year, 5-year, and 10-year horizons, reflecting durable capital efficiency
  • US formulations segment grew 27.2% YoY in FY25 and now accounts for 47.5% of total revenue, providing strong dollar-denominated earnings
  • Q4 FY25 EBITDA margin expanded 310 bps YoY to 32.6%, with EBITDA of ₹21,255 Mn up 30.4% YoY
  • Net debt-to-equity ratio of -0.20x as of March 2025 means the company is effectively net cash, providing significant financial flexibility
  • Saroglitazar NDA for Primary Biliary Cholangitis received FDA Priority Review with a PDUFA date of November 2026, representing a potential novel drug revenue stream
  • ZYCUBO (copper histidinate) received FDA approval in January 2026 as the first-ever treatment for Menkes disease, demonstrating specialty pipeline execution
  • 5-year compounded profit growth of 18.8% CAGR alongside 12% sales CAGR over the same period shows operating leverage in the business model
Bear Case 8
  • TTM compounded profit growth has decelerated sharply to just 5% versus the 32% 3-year CAGR, suggesting recent earnings momentum is fading
  • FDA issued a warning letter dated June 2, 2026 for CGMP violations at the Baddi facility, marking the second warning letter in under two years after the August 2024 letter for a different site
  • Q1 FY27 net profit fell 36% YoY to ₹9,398 Mn, a significant sequential and year-on-year decline
  • Dividend yield of just 0.09% offers negligible income return to shareholders at current prices
  • PE of 24.3x is not cheap for a pharma company whose near-term profit growth has slowed to single digits on a TTM basis
  • Heavy US revenue concentration at 47.5% exposes the company to pricing pressure from US drug policy changes, channel consolidation, and currency fluctuations
  • Recurring FDA compliance issues across multiple plants create ongoing risk of import alerts or product approval delays for the US business
  • 1-year stock CAGR of 7% significantly lags the 3-year CAGR of 20%, suggesting the market has already priced in much of the growth story

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 3h ago
Headwinds 2
  • HC bars Dabrafenib generic launch Aug 18

    High court restrained Zydus from launching Dabrafenib (Novartis-patented compound), blocking a potential oncology revenue stream and highlighting patent dispute risks with originator pharma companies.

  • Q1 FY27 profit drops 36% YoY Aug 21

    Consolidated net profit fell 36% YoY to ₹939.8 crore in Q1 FY27 despite 22% revenue growth, with EBITDA margin contracting 770 bps YoY to 24.1%.

Positives 4
  • Macquarie maintains Outperform at ₹1,285 Aug 27

    Macquarie reiterated Outperform with a ₹1,285 target, noting branded businesses at 55% of revenue expected to exceed two-thirds medium-term, driving EBITDA margins to 27-28%. Saroglitazar (FY28 launch) guided for $250-300M peak US sales.

  • US FDA approves Ascorbic Acid injection Aug 21

    Zydus received FDA approval for Ascorbic Acid injection with 180-day CGT exclusivity; brand product has ~$11.6M annual US sales. Total US portfolio now at 448 approvals and 513 ANDA filings as of June 2026.

  • India outperformance guided 300-500 bps Aug 27

    Management expects to outperform the Indian pharma market by 300-500 bps in FY27, supported by oncology, biosimilars, nephrology and Semaglutide supply partnerships with Torrent and Lupin.

  • 30+ US product launches annually Aug 27

    Company targets launching over 30 products annually in the US, with innovative products already contributing ~10% of US revenue at high profitability.

Neutral 6
  • Treasury subsidiary in GIFT City Aug 26

    Incorporated Zydus Global Treasury Centre IFSC Ltd on Aug 25 in GIFT City with ₹5 crore capital to centralise treasury operations and leverage IFSC tax/regulatory benefits.

  • J.P. Morgan India Conference Sep 11

    Zydus Lifesciences will present at J.P. Morgan India Conference scheduled for September 21, 2026.

  • 31st AGM held August 11 Sep 1

    Annual General Meeting conducted via video conference on August 11, 2026 with key management and statutory auditors in attendance.

  • Promoter group share transmission Aug 24

    Promoter group member Prashant Babubhai Patel acquired 32,577 shares via estate transmission from Late Jasodaben Babubhai Patel.

  • ESGRAIL ESG rating of 60 Aug 21

    Received an independent ESG rating score of 60 from SEBI-registered provider ESGRAIL based on public data.

  • Investor roadshow in Asia Aug 17

    Management scheduled non-deal roadshow in Singapore and Hong Kong from August 24-26, 2026 for institutional investor engagement.

TL;DR: Zydus Lifesciences is executing a strategic pivot toward higher-margin branded and innovative businesses, with Macquarie validating the thesis at a ₹1,285 target and Saroglitazar offering a significant US opportunity by FY28. Revenue growth remains strong at 22% YoY, but the sharp 36% profit decline and 770 bps margin contraction in Q1 FY27 need monitoring, alongside patent litigation risks like the Dabrafenib block. The trend is constructive if the branded revenue mix shift materializes and margins recover toward the guided 27-28% range over the medium term.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
5,140
4,369
4,505
5,534
6,208
5,237
5,269
6,528
6,574
6,123
6,864
7,587
8,017
Expenses
3,634
3,223
3,403
3,903
4,124
3,776
3,882
4,402
4,485
4,107
5,048
5,033
6,088
Operating Profit
1,505
1,146
1,102
1,630
2,084
1,461
1,388
2,126
2,088
2,016
1,816
2,554
1,929
OPM %
29%
26%
24%
29%
34%
28%
26%
33%
32%
33%
26%
34%
24%
Other Income
21
53
60
160
63
68
57
-139
155
75
26
-263
88
Interest
18
9
20
35
32
25
32
77
85
101
130
123
156
Depreciation
180
184
195
205
215
234
229
238
238
302
360
508
555
PBT
1,328
1,006
947
1,550
1,900
1,271
1,184
1,672
1,921
1,687
1,353
1,660
1,307
Tax %
16%
22%
23%
21%
23%
29%
15%
25%
23%
27%
29%
19%
27%
Net Profit
1,134
803
790
1,246
1,482
920
1,026
1,244
1,521
1,239
1,023
1,341
990
EPS in Rs
10.74
7.91
7.8
11.75
14.11
9.06
10.17
11.64
14.58
12.51
10.36
12.65
9.42
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8,651
9,427
9,376
11,905
13,166
14,253
15,102
15,265
17,237
19,547
23,242
27,148
28,592
Expenses
6,896
7,095
7,474
9,074
10,174
11,455
11,758
11,923
13,378
14,163
16,183
18,673
20,276
Operating Profit
1,756
2,332
1,902
2,831
2,991
2,798
3,344
3,342
3,860
5,384
7,058
8,475
8,316
OPM %
20%
25%
20%
24%
23%
20%
22%
22%
22%
28%
30%
31%
29%
Other Income
45
112
127
111
183
-264
-171
2,581
-422
293
50
-7
-74
Interest
68
53
45
91
194
342
164
127
130
81
166
439
510
Depreciation
287
292
373
539
599
696
725
713
723
764
916
1,408
1,725
PBT
1,446
2,099
1,612
2,312
2,382
1,495
2,285
5,084
2,585
4,832
6,027
6,621
6,007
Tax %
18%
8%
8%
24%
22%
21%
6%
10%
23%
20%
23%
24%
—
Net Profit
1,188
1,964
1,517
1,810
1,899
1,204
2,185
4,618
2,092
3,973
4,673
5,124
4,593
EPS in Rs
11.24
18.89
14.53
17.35
18.06
11.49
20.84
43.83
19.37
38.36
44.97
50.09
44.94
Div. Payout %
21%
17%
22%
20%
19%
30%
17%
6%
31%
8%
24%
2%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
102
102
102
102
102
102
102
102
101
101
101
101
Reserves
4,149
5,597
6,858
8,642
10,284
10,273
12,890
16,897
17,415
19,729
23,852
27,011
Borrowings
2,651
2,442
5,207
5,407
7,899
7,986
4,584
4,221
1,195
804
3,213
12,496
Other Liabilities
2,144
2,208
2,937
3,632
4,945
5,115
6,189
6,421
6,851
8,201
9,523
11,065
Total Liabilities
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Fixed Assets
3,352
3,748
5,755
6,483
12,164
12,230
12,133
12,253
11,521
12,368
13,134
24,106
CWIP
798
951
1,543
1,527
837
742
783
661
1,201
2,423
2,692
3,698
Investments
154
416
435
746
674
765
830
3,288
1,547
1,220
6,412
7,540
Other Assets
4,743
5,235
7,371
9,028
9,556
9,740
10,019
11,439
11,294
12,822
14,451
15,328
Total Assets
9,047
10,350
15,104
17,783
23,231
23,477
23,765
27,642
25,562
28,834
36,689
50,673
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
994
1,894
1,312
919
1,282
2,505
3,293
2,104
2,689
3,228
6,781
2,117
Investing
-465
-860
-2,872
-974
-3,977
-1,012
-835
1,137
1,178
-1,492
-8,363
-7,895
Financing
-351
-935
2,316
52
1,885
-1,094
-2,549
-868
-4,400
-1,810
1,995
5,807
Net Cash Flow
178
99
756
-3
-811
399
-90
2,373
-534
-75
414
28
Free Cash Flow
498
936
-1,623
-116
236
1,617
2,446
1,050
1,697
2,345
5,139
-530
CFO/OP
79
109
81
54
65
100
109
83
85
84
122
44
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
67
68
89
98
110
94
76
80
94
97
64
73
Inventory Days
175
158
193
211
208
207
227
245
197
202
227
282
Days Payable
125
154
165
167
149
151
155
141
123
125
131
142
Cash Conversion Cycle
118
71
116
142
169
150
148
184
168
175
160
212
Working Capital Days
6
-1
-34
17
10
-19
-6
19
70
88
3
-40
ROCE %
23%
28%
16%
18%
15%
11%
14%
13%
15%
22%
24%
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Life Science insights

62 extracted metrics + investor summaries across FY05–FY26.

Log in — free

Shareholding Pattern

Others1.38%Promot.75.01%Public5.45%FIIs6.88%DIIs11.27%As ofJun 2026

Documents

Frequently Asked Questions about Zydus Life Science

What does Zydus Lifesciences Ltd do?
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise...
Where is Zydus Lifesciences Ltd (ZYDUSLIFE) listed?
Zydus Lifesciences Ltd trades as ZYDUSLIFE on the NSE and under code 532321 on the BSE.
Which sector does Zydus Lifesciences Ltd belong to?
Zydus Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd has a market capitalisation of ₹1,11,330 Cr, which places it in the Large Cap band.
What is the PE ratio of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd trades at a PE ratio of 24.90, on earnings per share of ₹41.43, against a book value of ₹271.78 per share.
What is the 52-week high and low of Zydus Lifesciences Ltd?
Over the last 52 weeks Zydus Lifesciences Ltd has traded between ₹835.5 and ₹1,205.
Does Zydus Lifesciences Ltd pay dividends?
Zydus Lifesciences Ltd has a dividend yield of 0.09%.
What is the Return on Equity (ROE) of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd reported a return on equity of 16.99%. Its debt-to-equity ratio is 0.46.

Company Information

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Website zyduscadila.com
CEO Dr. Sharvil Pankajbhai Patel
Employees 27,917
Listed 2000-04-18
Face Value ₹ 1
Issued Size 1,00,62,33,990

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSLIFE.md for Zydus Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List